New York, May 16, 2024 - PRISM MarketView - The PRISM Emerging Cannabis Index currently does not have a single detractor as shares of cannabis stock are on the rise which is likely related to the recent announcement by the Department of Justice (DOJ). The DOJ has taken a major step in its commitment to reschedule marijuana to a lower-risk drug by announcing the formalization of its process.
The Drug Enforcement Administration (DEA) has submitted a notice of proposed rulemaking in the Federal Register this afternoon, triggering a 60-day comment period that will allow members of the public to submit remarks regarding the rescheduling proposal before it is finalized. In its first 30 days, parties can request a hearing regarding the declassification proposal. Once the DEA reviews all public comments and hearings, it will issue a final order to reschedule marijuana. The process in its entirety could take anywhere from a few months to a year.
Upon its rescheduling, many new benefits and potential opportunities will be presented. Federal scientists will be able to research and study the medical benefits of cannabis, pharma companies may get involved in selling and distributing the drug in states where legal, and the cannabis industry could thrive as significant tax burdens for businesses would be eliminated.
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
PRISM MarketView
646-863-6341
Prism MarketView | Stock Market News & Investment Opportunities